The IMMUWIN phase II will test the safety and anti-tumor efficacy of the combination of durvalumab and tremelimumab with either TACE or Y-90 SIRT. Patients will be randomized into two experimental arms, one receiving SIRT + Durvalumab + Tremelimumab, the other arm receiving TACE + Durvalumab + Tremelimumab. It will be determined whether the combination of immunotherapy with SIRT or TACE is more promising.
A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design